BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Up 20.6% in April

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 3,690,000 shares, a growth of 20.6% from the March 31st total of 3,060,000 shares. Based on an average daily volume of 1,410,000 shares, the short-interest ratio is currently 2.6 days.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock traded down $1.26 during mid-day trading on Friday, reaching $80.91. 2,257,132 shares of the company traded hands, compared to its average volume of 1,697,110. BioMarin Pharmaceutical has a fifty-two week low of $76.02 and a fifty-two week high of $99.56. The firm’s fifty day moving average is $87.58 and its two-hundred day moving average is $89.14. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.51 and a quick ratio of 1.57. The company has a market capitalization of $15.27 billion, a price-to-earnings ratio of 75.62, a price-to-earnings-growth ratio of 1.49 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $646.21 million during the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a net margin of 8.31% and a return on equity of 5.39%. BioMarin Pharmaceutical’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period last year, the firm posted $0.11 EPS. On average, equities research analysts expect that BioMarin Pharmaceutical will post 1.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BMRN has been the subject of several recent research reports. Robert W. Baird reduced their target price on shares of BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating for the company in a research note on Tuesday, January 30th. Canaccord Genuity Group cut their target price on BioMarin Pharmaceutical from $91.00 to $89.00 and set a “hold” rating for the company in a research note on Friday. Scotiabank upped their price target on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a “sector perform” rating in a research report on Thursday. Cantor Fitzgerald restated an “overweight” rating and issued a $110.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $107.50.

Insider Activity at BioMarin Pharmaceutical

In related news, Director Jean Jacques Bienaime sold 20,000 shares of the business’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the transaction, the director now directly owns 474,994 shares in the company, valued at $43,347,952.44. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock in a transaction on Friday, April 12th. The stock was sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the sale, the director now directly owns 474,994 shares in the company, valued at approximately $43,347,952.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Henry J. Fuchs sold 35,341 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the completion of the transaction, the insider now directly owns 212,117 shares in the company, valued at $18,068,126.06. The disclosure for this sale can be found here. Insiders have sold 103,229 shares of company stock valued at $9,062,967 over the last ninety days. Corporate insiders own 1.84% of the company’s stock.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in the business. KB Financial Partners LLC boosted its stake in shares of BioMarin Pharmaceutical by 51.3% in the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock worth $31,000 after buying an additional 118 shares during the last quarter. Lindbrook Capital LLC boosted its position in BioMarin Pharmaceutical by 259.8% in the 4th quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 278 shares in the last quarter. Castleview Partners LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $35,000. Benjamin F. Edwards & Company Inc. increased its holdings in shares of BioMarin Pharmaceutical by 135.3% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 249 shares in the last quarter. Finally, Jones Financial Companies Lllp acquired a new position in shares of BioMarin Pharmaceutical in the 4th quarter valued at $43,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.